31 citations
,
September 2006 in “The Journal of Clinical Endocrinology & Metabolism” Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.
October 2025 in “Journal of the Endocrine Society” The patient was satisfied with hormone therapy, and her epilepsy remained stable.
July 2025 in “Journal of Investigative Dermatology”
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
January 2026 in “Endocrinology”
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
18 citations
,
August 2012 in “Journal of The American Academy of Dermatology” Estrogen therapy helped regrow hair in a bald man.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
9 citations
,
July 2024 in “Internal Medicine Journal” Gender-affirming hormone therapy improves mental health and gender incongruence but requires careful management of cardiovascular and cancer risks.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
November 2025 in “JAAD Case Reports” Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
14 citations
,
December 2010 in “Seminars in Oncology” Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.
32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
Ayurveda-based care improved quality of life for breast cancer patients without serious side effects.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
6 citations
,
June 1983 in “Cancer” A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
1 citations
,
July 2015 in “AACE clinical case reports” Removing both ovaries treated the woman's excess male hormone symptoms.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
January 2024 in “Journal of surgical case reports” Removing an adrenal tumor can significantly reduce high androgen levels in postmenopausal women.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
164 citations
,
January 2003 in “Drugs”
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.